A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension (LOTUS)

Allergan

Status and phase: Completed; Phase 4

Conditions: Ocular Hypertension; Glaucoma, Open-Angle

Treatments: Drug: Bimatoprost 0.03%

Study type: Interventional

Funder types: Industry

Identifiers

NCT02061683

CN-BIM-0901

Details and patient eligibility

About

This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.

Enrollment: 263 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of open-angle glaucoma or ocular hypertension
• No use of Lumigan® in the past 3 months

Exclusion criteria

• Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

263 participants in 1 patient group

Bimatoprost 0.03%

Experimental group

Description:

Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.

Treatment:

Drug: Bimatoprost 0.03%